Published in Hepatitis Weekly, November 4th, 1996
According to researcher Magnus Lindh and colleagues, these findings indicate that such mutations represent a viral escape that reduces the host's immune response and, consequently, the necroinflammatory activity.
After its discovery in 1972, the hepatitis B e antigen (HBeAg) was found to be a useful marker of infectivity and liver damage. Seroconversion of the HBeAg antibody was shown to indicate a reduction in viral replication and clinical improvement. It later...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.